本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603309 证券简称：维力医疗 公告编号：2025-059 广州维力医疗器械股份有限公司 股权激励限制性股票回购注销实施公告 重要内容提示： 回购注销原因：根据公司《第一期限制性股票激励计划（草案）》的相关规 定，因公司层面考核指标未达成原因，经公司董事会和股东大会审议通过，公司决 定对77名激励对象持有的已获授但尚未解除限售的合计996,600股限制性股票予以 回购注销。 本次注销股份的有关情况： | 回购股份数量 | 注销股份数量 | 注销日期 | | --- | --- | --- | | 996,600 股 | 996,600 股 | 2025-10-22 | 一、本次限制性股票回购注销已履行的决策程序和信息披露情况 广州维力医疗器械股份有限公司（以下简称"公司"）分别于 2025 年 7 月 30 日召开的第五届董事会第十六次会议、2025 年 8 月 15 日召开的公司 2025 年第一次 临时股东大会审议通过了《关于回购注销公司第一期限制性股票激励计划已 ...

的法律意见书 国浩津法意字（2025）第 356号 致:广州维力医疗器械股份有限公司 国浩律师（天津）事务所（以下简称"本所"）接受广州维力医疗器械股份有 限公司（以下简称"维力医疗"、"上市公司"或"公司"）的委托,作为公司第一期 限制性股票激励计划(以下简称"本激励计划"或"《激励计划(草案)》")的专 项法律顾问,根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》(以下简称"《证券法》")、中国证券监督管理委员会(以 下简称"中国证监会"）、《上市公司股权激励管理办法》〈以下简称"《管理办 法》")等法律、行政法规、部门规章及其他规范性文件(以下简称"法律法规") 和《广州维力医疗器械股份有限公司章程》（以下简称"《公司章程》"）、《广 州维力医疗器械股份有限公司第一期限制性股票激励计划》的有关规定,就公司 本次回购注销部分已授予限制性股票(以下简称"本次回购注销")所涉及的相关 事项,出具本法律意见书。 國浩律師事務所 GRANDALL LAW FIRM 天津市和平区曲阜道 38 号中国人寿金融中心 28 层 邮编：300042 电话：022-85586588 传真：0 ...

Core Viewpoint - The announcement details the pledge and release of shares by a major shareholder of Guangzhou Weili Medical Instruments Co., Ltd., indicating significant movements in shareholding and potential implications for the company's financial stability and investor confidence [2][3][4]. Summary by Sections Share Pledge Details - As of the announcement date, the shareholder Guangzhou Songwei Enterprise Management Consulting Co., Ltd. holds 39,064,856 shares, representing 13.34% of the total share capital, with 14,600,000 shares pledged, accounting for 37.37% of their holdings and 4.99% of the total share capital [2]. - On October 9, 2025, Guangzhou Songwei registered a pledge of part of its shares, with no involvement in major asset restructuring or performance compensation guarantees [2]. Release of Pledged Shares - On October 20, 2022, Guangzhou Songwei pledged 14,000,000 unrestricted circulating shares to China Merchants Securities Co., Ltd., with the pledge period from October 20, 2022, to October 19, 2023 [3]. - On October 19, 2023, the aforementioned shares were extended for pledge, and an additional 5,350,000 unrestricted circulating shares were pledged [3]. - On October 18, 2024, the pledge of 19,350,000 shares was also extended, with details disclosed in previous announcements [4]. - Recently, on October 10, 2025, Guangzhou Songwei completed the early redemption of the pledged shares, with the release procedures finalized through the China Securities Depository and Clearing Corporation [4]. Cumulative Pledged Shares - As of the announcement date, the cumulative pledged shares by Guangzhou Songwei and its concerted parties are detailed, indicating ongoing management of share pledges [4].

证券代码：603309 证券简称：维力医疗 公告编号：2025-058 广州维力医疗器械股份有限公司 关于股东部分股份质押及解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 截至本公告披露日，公司股东广州松维企业管理咨询有限公司合计持有公司股 份 39,064,856 股，占公司总股本的 13.34%，累计质押公司股份 14,600,000 股， 占其所持股份比例的 37.37%，占公司总股本的 4.99%。 广州维力医疗器械股份有限公司（以下简称"公司"、"维力医疗"）于近日接到 公司股东广州松维企业管理咨询有限公司（以下简称"广州松维"）函告，获悉其将 持有的本公司部分股份办理了质押及解除质押的登记手续，具体事项如下： 一、本次股份质押基本情况： 广州松维于 2025 年 10 月 9 日将持有的本公司部分股份办理了质押登记手续， 具体事项如下: | | 是否 | | | | | | | | 占公 | | | --- | --- | --- | --- | --- | --- | --- | ...

Group 1 - The core point of the article is that Weili Medical (SH 603309) announced significant shareholder information and revenue composition for the year 2024 [1] - As of the announcement date, the shareholder Guangzhou Songwei Enterprise Management Consulting Co., Ltd. holds approximately 39.06 million shares, accounting for 13.34% of the total share capital [1] - The company has pledged a total of 14.6 million shares, which represents 37.37% of the shares held by the shareholder and 4.99% of the total share capital [1] Group 2 - For the fiscal year 2024, Weili Medical's revenue composition is primarily from medical devices, which account for 98.04% of total revenue, while other businesses contribute 1.96% [1] - As of the latest report, Weili Medical has a market capitalization of 3.9 billion yuan [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州维力医疗器械股份有限公司（以下简称"公司"、"维力医疗"）全资子公司 海南维力医疗科技开发有限公司（以下简称"海南维力"）于近日收到海南省药品监 督管理局颁发的《中华人民共和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证的具体情况 注册证编号：琼械注准 20252080088 注册人名称：海南维力医疗科技开发有限公司 证券代码：603309 证券简称：维力医疗 公告编号：2025-057 广州维力医疗器械股份有限公司 关于全资子公司产品获得二类医疗器械注册证的公告 批准日期：2025年09月23日 有效期至：2030年09月22日 二、对公司的影响 此次子公司海南维力取得上述医疗器械注册证，有利于丰富子公司产品种类， 有助于提高公司产品的市场竞争力，对公司经营将产生积极影响。 注册人住所：海口国家高新区美安生态科技新城美安三街 39 号 生产地址：海口国家高新区美安生态科技新城美安三街 39 号 产品名称：一次性使用无菌双腔型喉罩气道导管 结构及组成：由气囊、通气管、 ...

Core Viewpoint - Vily Medical (603309) has received a medical device registration certificate for a new product, a disposable sterile double-lumen laryngeal mask airway, from the Hainan Provincial Drug Administration, which is intended for use in anesthesia, sedation, and emergency ventilation support for patients [1] Group 1 - The product is designed for patients requiring short-term artificial airway establishment during anesthesia or sedation [1] - The device is also applicable in emergency and resuscitation scenarios for providing artificial ventilation support [1]

Core Viewpoint - The company, Weili Medical (603309.SH), has received a medical device registration certificate from the Hainan Provincial Drug Administration for its product, a disposable sterile double-lumen laryngeal mask airway catheter [1]. Group 1 - The product is named "disposable sterile double-lumen laryngeal mask airway catheter" [1]. - The registration was granted to the company's wholly-owned subsidiary, Hainan Weili Medical Technology Development Co., Ltd. [1]. - This development indicates the company's ongoing efforts to expand its product offerings in the medical device sector [1].

Core Viewpoint - The company, Weili Medical, has received a medical device registration certificate for its product, a disposable sterile double-lumen laryngeal mask airway catheter, from the Hainan Provincial Drug Administration [1] Group 1 - Weili Medical's wholly-owned subsidiary, Hainan Weili Medical Technology Development Co., Ltd., is responsible for the newly certified product [1]

Investment Rating - The report recommends focusing on leading companies in various segments of the high-value consumables and medical device sectors, indicating a positive outlook for recovery and growth in these areas [4][30]. Core Insights - High-value consumables have begun to recover from the impacts of centralized procurement, with leading companies regaining profitability levels seen before the procurement initiatives [4][32]. - The medical device and IVD sectors are expected to show signs of recovery, with significant improvements anticipated in financial performance by Q3 2025 for device companies and by Q4 2025 for IVD companies [4][30]. - The report highlights specific high-growth segments, including vascular intervention, orthopedics, and IVD, suggesting that these areas will continue to attract investment due to their growth potential and market dynamics [4][30]. Summary by Sections Medical Devices - The medical device sector is projected to experience a revenue decline in 2024, with a further drop of -5.18% expected in the first half of 2025, but recovery is anticipated thereafter [9][12]. - Despite revenue challenges, the overall gross margin and net profit margin have remained stable, with R&D expenses increasing from approximately 7% pre-pandemic to around 10% currently [10][12]. - Companies in the imaging equipment segment are expected to see improved performance in Q3 2025 as inventory issues are resolved and new procurement projects are executed [13][18]. High-Value Consumables - The high-value consumables sector has shown revenue growth in the first half of 2025, indicating a recovery from previous declines, with profit margins returning to levels seen in 2021 [32][33]. - Specific segments such as vascular intervention and orthopedics are highlighted for their resilience and growth potential, with companies like Huatai Medical and Weigao Orthopedics showing significant revenue increases [38][43]. IVD and Other Segments - The IVD sector is expected to see improvements by Q4 2025, with overall industry recovery projected for the first half of 2026 [4][30]. - The report emphasizes the importance of innovation and market expansion for companies in the rehabilitation and home medical device sectors, with firms like Sanofi and Kefu Medical showing strong growth despite market challenges [24][26].